At Detroit Life Sciences, we are building a resilient future for healthcare by addressing critical challenges in the supply of intravenous (IV) solutions. Our advanced manufacturing capabilities are designed to meet the growing demand for high-quality IV fluids used in hospitals, outpatient clinics, and emergency care settings across the United States.

With a $500 million investment in a state-of-the-art production facility in Detroit, Michigan, we are strengthening domestic manufacturing and reducing reliance on global supply chains. The facility, spanning five acres and featuring a 150-175,000 sq ft building, will play a key role in enhancing national preparedness and healthcare system reliability.

Our solutions are guided by values of unity, protection, and service to the greater good. We are not only focused on delivering essential medical products but also on driving innovation, supporting sustainable healthcare systems, and improving patient outcomes nationwide.

In parallel with our operations in Saudi Arabia, Detroit Life Sciences is advancing a global strategy to ensure reliable access to life-saving IV solutions—wherever and whenever they are needed.

State-of-the-art facility ensuring safe, effective intravenous solutions for local healthcare systems.

Addressing global IV solution shortages through localized production in the U.S., GCC, MENA, and beyond.

Improving patient outcomes while reducing healthcare costs and supply chain vulnerabilities effectively.

Detroit Life Sciences addresses the global shortage of intravenous solutions by establishing a state-of-the-art manufacturing facility, ensuring safe and effective products for healthcare systems in the U.S. and beyond.

Our commitment to localizing the pharmaceutical industry in the U.S. enhances supply chain resilience and reduces healthcare costs while improving patient outcomes across the region.

By responding to increased global demand for IV solutions, our facility mitigates supply chain vulnerabilities, ensuring that healthcare providers have access to essential intravenous therapies when they need them most.